Eliana Merle
Stock Analyst at UBS
(3.79)
# 715
Out of 5,090 analysts
96
Total ratings
52.11%
Success rate
9.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $27.70 | +44.40% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $73.64 | +11.35% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $3.33 | +170.27% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $5.24 | +358.02% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $34.47 | -73.89% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $577.30 | -9.41% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $44.41 | -54.97% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $205.44 | +49.44% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $53.40 | +113.48% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $458.12 | +20.06% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $22.26 | -46.09% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.34 | +241.88% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.12 | +7.42% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.79 | +64.19% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $66.62 | +5.07% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $23.63 | +86.20% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $54.55 | +99.82% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.39 | +58.27% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $79.64 | -10.85% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $21.50 | +30.23% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.39 | +87.79% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $4.13 | -27.36% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $96.25 | +36.10% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $24.34 | -79.46% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $29.36 | -38.69% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $21.33 | +96.91% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.41 | +26.36% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $13.16 | +257.14% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.90 | +61.62% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $31.59 | +324.18% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $27.70
Upside: +44.40%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $73.64
Upside: +11.35%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $3.33
Upside: +170.27%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $5.24
Upside: +358.02%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $34.47
Upside: -73.89%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $577.30
Upside: -9.41%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $44.41
Upside: -54.97%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $205.44
Upside: +49.44%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $53.40
Upside: +113.48%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $458.12
Upside: +20.06%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $22.26
Upside: -46.09%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.34
Upside: +241.88%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.12
Upside: +7.42%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.79
Upside: +64.19%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $66.62
Upside: +5.07%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $23.63
Upside: +86.20%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $54.55
Upside: +99.82%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.39
Upside: +58.27%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $79.64
Upside: -10.85%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $21.50
Upside: +30.23%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.39
Upside: +87.79%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $4.13
Upside: -27.36%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $96.25
Upside: +36.10%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $24.34
Upside: -79.46%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $29.36
Upside: -38.69%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $21.33
Upside: +96.91%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $17.41
Upside: +26.36%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $13.16
Upside: +257.14%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.90
Upside: +61.62%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $31.59
Upside: +324.18%